Evolocumab significantly reduces risk of cardiovascular events
Evolocumab, one of the new targeted PCSK9 inhibitor drugs that has been shown to dramatically lower levels of low-density lipoprotein (LDL), or "bad" cholesterol, also significantly lowers the risk of cardiovascular events ...
Mar 17, 2017
0
0